BioSpace News Archive

PCI Pharma Services (PCI), a leading biopharmaceutical outsourcing services provider, has solidified its leadership position in the EU with strategic investment to deepen its presence in Ireland and expand its European foothold.

Discovery Behavioral Health, a leading nationwide provider of mental health services, has opened a facility in Orlando, FL, devoted exclusively to the treatment of adolescents and young adults.

“Hepatitis C virus remains a significant public health issue, but effective therapeutic options have helped patients to receive important curative treatments,” said Debra Birnkrant, M.D., director of the Division of Antiviral Products within the FDA’s Center for Drug Evaluation and Research.

UnitedHealthcare and Optum, the health benefits and services companies of UnitedHealth Group (NYSE: UNH), are taking action to help people who may be affected by Tropical Storm Dorian, which is expected to make landfall later this week.

The Crohn’s & Colitis Foundation’s New England Chapter proudly announces its 50th anniversary, commemorating five decades of volunteer leadership, research initiatives, disease awareness, patient support, and advocacy programs.

According to a new guideline, the answer is yes. The guideline, developed by the American Academy of Neurology (AAN), recommends that people with MS receive recommended vaccinations, including yearly flu shots.

Neurocrine Biosciences, Inc. announced that Neurocrine Biosciences management will present at the following investor conferences

MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for its fiscal year ended June 30, 2019.

ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (OTC: IMUC) today announced receipt of payment of $500,000 in conjunction with the completion of a transaction for the purchase of substantially all of ImmunoCellular’s remaining assets, including its preclinical and clinical programs, technology, intellectual property and know-how.

REGENXBIO Inc. announced that it will present at the following September investor conferences